Echo Therapeutics Appoints Christopher Schnittker as CFO
Echo Therapeutics has appointed Christopher Schnittker, certified public accountant (CPA), as chief financial officer (CFO). Schnittker is a senior executive with more than 20 years of financial management, reporting and corporate governance experience in the biotechnology and pharmaceutical industries. Schnittker will report to chief executive officer (CEO) Patrick Mooney.
At this critical stage in product development and company growth, it became necessary for Echo to separate the functions of chief operating officer and CFO that were being performed by Harry Mitchell. Schnittker will take over the responsibilities of managing the financial function so that Mitchell can focus entirely on his role as COO, leveraging his time to bringing the Prelude SkinPrep System and Symphony tCGM system to market, as well as broadening the product pipeline.
Schnittker brings a broad base of financial experience to Echo Therapeutics. Most recently, he served as vice president – administration, corporate secretary and chief accounting officer (CAO) of Soligenix, a biotechnology company. Prior to that, Schnittker served as the senior vice president (SVP) and CFO for VioQuest Pharmaceuticals, Micromet, Cytogen Corporation, and Genaera Corporation, all biotechnology companies based around the Philadelphia area. Schnittker has also held prior financial management positions at GSI Commerce, Rhone-Poulenc Rorer (now part of Sanofi-Aventis), and PricewaterhouseCoopers (PwC). He received his BA degree in Economics and Business from Lafayette College and is a CPA licensed in the State of New Jersey.